Antitumor efficacy of intermittent low‐dose erlotinib plus sulindac via MHC upregulation and remodeling of the immune cell niche is a research paper published in International Journal of Cancer (2025). On theSindex it has a DataRank of 0.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Division of Cancer Prevention, National Cancer Institute
Grant: P30 CA016672
Division of Cancer Prevention, National Cancer Institute
Grant: RO1 CA122959
Division of Cancer Prevention, National Cancer Institute
Grant: RO1 CA257559
Division of Cancer Prevention, National Cancer Institute
Grant: T.O. 75N91019D00021
Division of Cancer Prevention, National Cancer Institute
Grant: T.O. 75N91019F00130
CLC NIH HHS
Grant: 75N90019D00021
NCI NIH HHS
Grant: R01 CA122959
NCI NIH HHS
Grant: 75N91019D00021
NIAID NIH HHS
Grant: 75N93019D00021
NIEHS NIH HHS
Grant: 75N96024D00004
CLC NIH HHS
Grant: 75N90024D00004
ORFDO NIH HHS
Grant: 75N99019D00021
NCI NIH HHS
Grant: R01 CA257559
FWCI
0.00
Citation Percentile
0.1%
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals